Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clobazam for intractable pediatric epilepsy

R D Sheth1, G M Ronen, K J Goulden

  • 1Department of Neurology and Pediatrics, West Virginia University, Morgantown 26506-9180, USA.

Journal of Child Neurology
|May 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pre-treatment clinical assessment in head and neck cancer: United Kingdom National Multidisciplinary Guidelines.

The Journal of laryngology and otology·2016
Same author

Surgical management of medullary thyroid cancer: which guidelines should we follow?

The Journal of laryngology and otology·2015
Same author

Development and validation of a generic scale for use in transition programmes to measure self-management skills in adolescents with chronic health conditions: the TRANSITION-Q.

Child: care, health and development·2014
Same author

Evidence that temporal lobe is a default area in absence epilepsy.

Epilepsy & behavior : E&B·2012
Same author

History of cesarean section associated with childhood onset of T1DM in Newfoundland and Labrador, Canada.

Journal of environmental and public health·2012
Same author

Thalamofrontal neurodevelopment in new-onset pediatric idiopathic generalized epilepsy.

Neurology·2011
Same journal

Assessing Sudden Unexpected Death in Epilepsy (SUDEP), Mortality, and Suicide in Pediatric Epilepsy from the lens of Healthcare Disparities: Data From a Scoping Review.

Journal of child neurology·2026
Same journal

The Importance of Accessible, Patient-Focused Language in the Age of the Electronic Medical Record.

Journal of child neurology·2026
Same journal

Genetic Etiologies and Risk Factors for Regressive Autism and Childhood Disintegrative Disorder: A Scoping Review.

Journal of child neurology·2026
Same journal

Birmingham, 1963.

Journal of child neurology·2026
Same journal

Hyperintensity on Diffusion-Weighted Imaging in a MELAS Patient Does Not Necessarily Mean Cytotoxic Edema.

Journal of child neurology·2026
Same journal

Neuromuscular Symptoms of <i>ORAI1</i>-Related Immunodeficiency.

Journal of child neurology·2026
See all related articles

Clobazam add-on therapy helped 65% of children with refractory epilepsy achieve seizure reduction. However, behavioral side effects led to withdrawal in 35% of patients.

Area of Science:

  • Pediatric Neurology
  • Clinical Pharmacology

Background:

  • Refractory epilepsy affects many children, often with developmental delays.
  • Existing treatments may not provide adequate seizure control.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of add-on clobazam therapy in children with refractory epilepsy.
  • To assess the impact of clobazam on seizure frequency and identify potential side effects.

Main Methods:

  • A 5-year observational study of 63 children with refractory epilepsy.
  • Children received clobazam as add-on therapy, with follow-up ranging from 15 to 64 months.
  • Dosage averaged 0.8 mg/kg daily.

Main Results:

  • 65% of children experienced significant seizure reduction (41% seizure-free or >90% reduction, 24% with 50-90% reduction).

Related Experiment Videos

  • 35% of patients discontinued clobazam due to side effects or tolerance.
  • Reported side effects included behavioral issues (aggression, hyperactivity, depression) and insomnia.

    • Conclusions:

    • Clobazam is a potentially effective add-on treatment for pediatric refractory epilepsy.
    • Clinical utility can be limited by significant behavioral side effects in a subset of patients.